MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314270 | Name: Tenofovir alafenamide free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tenofovir alafenamide, also known as TAF and GS-7340, is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of tenofovir. By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP). Tenofovir alafenamide fumarate was approved in November 2015 for treatment of HIV-1.

Chemical Structure

Tenofovir alafenamide free base
Tenofovir alafenamide free base
CAS#379270-37-8 (free base)

Theoretical Analysis

MedKoo Cat#: 314270

Name: Tenofovir alafenamide free base

CAS#: 379270-37-8 (free base)

Chemical Formula: C21H29N6O5P

Exact Mass: 476.1937

Molecular Weight: 476.47

Elemental Analysis: C, 52.94; H, 6.13; N, 17.64; O, 16.79; P, 6.50

Price and Availability

Size Price Availability Quantity
100mg USD 150.00 Ready to ship
200mg USD 250.00 Ready to ship
500mg USD 450.00 Ready to ship
1g USD 750.00 Ready to ship
2g USD 1,250.00 Ready to ship
5g USD 2,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
379270-38-9 (fumarate) 1392275-56-7 (hemifumarate) 379270-37-8 (free base)
Synonym
GS7340; GS-7340; GS 7340; TAF; Tenofovir alafenamide; Genvoya.
IUPAC/Chemical Name
(S)-isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate
InChi Key
LDEKQSIMHVQZJK-AZFZMOAFSA-N
InChi Code
InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33?/m1/s1
SMILES Code
C[C@H](N[P@@](OC1=CC=CC=C1)(CO[C@H](C)CN2C=NC3=C(N)N=CN=C23)=O)C(OC(C)C)=O
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#379270-38-9 =Tenofovir alafenamide fumarate, 1:1 CAS#1392275-56-7= Tenofovir alafenamide hemifumarate, 2:1 CAS#379270-37-8 = Tenofovir alafenamide
Solvent mg/mL mM
Solubility
DMSO 73.0 153.21
Water 3.3 7.01
Ethanol 55.0 115.43
DMF 25.0 52.47
PBS (pH 7.2) 2.0 4.20
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 476.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Merchant E, Solleveld P, Gibas K, Krakower D. Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study. PLoS One. 2024 Dec 5;19(12):e0311591. doi: 10.1371/journal.pone.0311591. PMID: 39636888; PMCID: PMC11620414. 2: Daly MB, Dinh C, Holder A, Rudolph D, Ruone S, Swaims-Kohlmeier A, Khalil G, Sharma S, Mitchell J, Condrey J, Kim D, Pan Y, Curtis K, Williams P, Spreen W, Heneine W, García-Lerma JG. SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity. Nat Commun. 2024 Dec 4;15(1):10550. doi: 10.1038/s41467-024-54783-0. PMID: 39632836; PMCID: PMC11618496. 3: Chen RY, Lyu XY, Huang S, Li WZ, Zhai ZZ, Wang YH, Pan YJ, Zeng QL. [Comparative therapeutic efficacy of tenofovir amibufenamide versus tenofovir alafenamide in the treatment of patients with chronic hepatitis B: a real-world single- center study]. Zhonghua Gan Zang Bing Za Zhi. 2024 Nov 20;32(11):976-983. Chinese. doi: 10.3760/cma.j.cn501113-20240319-00142. PMID: 39623572. 4: Chang Z, Zhu H, Zhang Y, Chen Y, Li J, Qin J, Zhu Y, Wei H, Yang Y, Zou M, Qian F, Hu Z. Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations. Chin Med J (Engl). 2024 Nov 20;137(22):2758-2760. doi: 10.1097/CM9.0000000000003317. Epub 2024 Oct 25. PMID: 39623550; PMCID: PMC11611234. 5: Aldredge A, Gunthel C, Sheth AN. Elective Surgery for People With HIV With Low CD4 Cell Count. JAMA Intern Med. 2024 Dec 2. doi: 10.1001/jamainternmed.2024.6446. Epub ahead of print. PMID: 39621327. 6: Liu Y, Wang R, Sun L, Li A, Li Z, Kang Q, Feng Y, Lv S, Zhai Y, Li R, Hua W, Wang X, Gao Y, Wang Z, Feng Y, Han J, Jia L, Wang X, Zhang B, Li H, Li J, Zhang T, Wu H, Li L, Dai L. HIV-1 viral decay in blood and semen in antiretroviral- naïve adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide. Int J Antimicrob Agents. 2024 Nov 27:107396. doi: 10.1016/j.ijantimicag.2024.107396. Epub ahead of print. PMID: 39612994. 7: He Y, Huang X, Ye Y, Xu H. Clinical management of hypophosphatemic osteomalacia induced by adefovir and tenofovir: Insights from a case report. Medicine (Baltimore). 2024 Nov 29;103(48):e40746. doi: 10.1097/MD.0000000000040746. PMID: 39612388; PMCID: PMC11608679. 8: Rossetti B, Ferrara M, Taramasso L, Bai F, Lombardi F, Ciccarelli N, Durante M, Alladio F, Bonazza F, Rancan I, Montagnani F, Di Biagio A, Monforte AD, Zazzi M, Fabbiani M; for DOBINeuro study group. Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial. Infect Dis Ther. 2024 Nov 29. doi: 10.1007/s40121-024-01083-1. Epub ahead of print. PMID: 39612159. 9: Funderburg NT, Huang SSY, Cohen C, Ailstock K, Cummings M, Lee JC, Ng B, White K, Wallin JJ, Downie B, McComsey GA. Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens. Front Immunol. 2024 Nov 12;15:1488799. doi: 10.3389/fimmu.2024.1488799. PMID: 39600696; PMCID: PMC11590120. 10: Markakis K, Tsachouridou O, Georgianou E, Pilalas D, Nanoudis S, Metallidis S. Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives. Life (Basel). 2024 Oct 24;14(11):1367. doi: 10.3390/life14111367. PMID: 39598166; PMCID: PMC11595778. 11: Lanzafame M, Lattuada E, Delama A, Mori G, Vento S. Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up. Biomedicines. 2024 Nov 15;12(11):2620. doi: 10.3390/biomedicines12112620. PMID: 39595184; PMCID: PMC11592082. 12: Agrahari V, Peet MM, Chandra N, Ramalingam P, Gupta PK, Jonnalagadda S, Singh ON, McCormick TJ, Doncel GF, Clark MR. Formulation development of dual- compartment topical inserts combining tenofovir alafenamide and elvitegravir for flexible on-demand HIV prevention. J Control Release. 2024 Dec 6;377:842-854. doi: 10.1016/j.jconrel.2024.11.062. Epub ahead of print. PMID: 39592025. 13: Shahzil M, Chaudhary AJ, Kashif T, Qureshi AA, Muhammad A, Khan F, Faisal MS, Khaqan MA, Ali H, Dababneh Y, Moonka D. Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. JGH Open. 2024 Nov 24;8(11):e70055. doi: 10.1002/jgh3.70055. PMID: 39588267; PMCID: PMC11586466. 14: Penner J, Ombajo LA, Nkuranga J, Otieno E, Nyakoe D, Wanjohi R, Mbewa V, Ndinya F, Eshiwani S, Wahome S, Bhagani S, Pozniak A, Gregson CL. High prevalence of osteoporosis among virally suppressed older people (≥60 years) living with HIV. HIV Med. 2024 Nov 21. doi: 10.1111/hiv.13741. Epub ahead of print. PMID: 39569696. 15: Webb EL, Petkov S, Yun H, Else L, Lebina L, Serwanga J, Pillay AAP, Seiphetlo TB, Mugaba S, Namubiru P, Odoch G, Opoka D, Ssemata AS, Kaleebu P, Khoo S, Martinson N, Fox J, Gray CM, Herrera C, Chiodi F. Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis. Front Immunol. 2024 Nov 6;15:1415475. doi: 10.3389/fimmu.2024.1415475. PMID: 39569196; PMCID: PMC11576434. 16: Lee SY, Lin YC, Chen CP, Cheng SH, Chang SY, Ku SY, Cheng CY. Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. PLoS One. 2024 Nov 20;19(11):e0314003. doi: 10.1371/journal.pone.0314003. PMID: 39565750; PMCID: PMC11578452. 17: Cecchini D, Brizuela M, Seleme MS, Mingrone MV, Copertari G, Bacelar B, Mauas R, Bottaro E, Cassetti I. Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Rev Esp Quimioter. 2024 Nov 20:cecchini20nov2024. doi: 10.37201/req/080.2024. Epub ahead of print. PMID: 39564653. 18: Di Perri G, Bonora S. Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies. New Microbiol. 2024 Nov;47(3):243-250. PMID: 39560035. 19: Barnett E, Kaginkar S, Schmitt K, Remling-Mulder L, Akkina R. A dual-purpose humanized mouse model for testing antiviral strategies against both SIV and HIV. Front Immunol. 2024 Nov 4;15:1491481. doi: 10.3389/fimmu.2024.1491481. PMID: 39559349; PMCID: PMC11570277. 20: Wang J, Jiang H, Zhang G, Dai X, Gao H, Li L. Real-World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation. J Med Virol. 2024 Nov;96(11):e70055. doi: 10.1002/jmv.70055. PMID: 39558790.